Tecentriq (atezolizumab) is a prescription drug that’s used to treat certain cancers. The drug comes as a solution that your doctor will inject. It’s usually given on a cycle every 2, 3, or 4 weeks.

The FDA is anticipated to make its decision on the regimen by 9 October 2026.

Evidence from a phase 3 trial does not support the addition of Tecentriq to a specific chemotherapy regimen with Avastin for patients with newly diagnosed stage 3 or 4 ovarian cancer. Adding Tecentriq ...

– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...

Last year, Roche’s Tecentriq became the first immuno-oncology treatment approved in triple negative breast cancer after it showed it could stall cancer progression in combination with Celgene’s ...

– Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone – – ...

Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave150 study, evaluating Tecentriq® ...

Roche’s new immuno-oncology drug Tecentriq is ready for its close-up in lung cancer. The PD-L1 checkpoint inhibitor nabbed FDA approval for patients who’ve failed on a previous treatment, putting it ...

Add Yahoo as a preferred source to see more of our stories on Google. The submission is supported by data from the Phase III ATOMIC study. Credit: Gorodenkoff / Shutterstock.com. (Gorodenkoff / ...